Sean Bohen

CIK: 0001831218

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (37.5%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (12.5%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

OLMA

Olema Pharmaceuticals, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

OLMA
Olema Pharmaceuticals, Inc.
Feb 2, 2026
Award(A)
Stock Option (Right to Buy)
Direct
850K shares-
OLMA
Olema Pharmaceuticals, Inc.
Feb 2, 2026
Award(A)
Performance Stock Options (Right to Buy)
Direct
275K shares-
OLMA
Olema Pharmaceuticals, Inc.
Dec 26, 2025
Gift(G)
Direct
8.5K shares-
OLMA
Olema Pharmaceuticals, Inc.
Feb 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
650K shares-
OLMA
Olema Pharmaceuticals, Inc.
Dec 11, 2024
Sale(S)
Direct
55.9K shares at avg. $8.66$484K
OLMA
Olema Pharmaceuticals, Inc.
Dec 11, 2024
Sale(S)
Direct
1.3K shares at avg. $9.39$12K
OLMA
Olema Pharmaceuticals, Inc.
Dec 10, 2024
Sale(S)
Direct
52.3K shares at avg. $9.37$490K
OLMA
Olema Pharmaceuticals, Inc.
Dec 9, 2024
Award(A)
Direct
204.8K shares-

		Type	Shares	Price		Ownership
Feb 2, 2026	OLMA Olema Pharmaceuticals, Inc.	Award(A) Stock Option (Right to Buy)	850,000	-	-	Direct
Feb 2, 2026	OLMA Olema Pharmaceuticals, Inc.	Award(A) Performance Stock Options (Right to Buy)	275,000	-	-	Direct
Dec 26, 2025	OLMA Olema Pharmaceuticals, Inc.	Gift(G)	8,500	-	-	Direct
Feb 28, 2025	OLMA Olema Pharmaceuticals, Inc.	Award(A) Stock Option (Right to Buy)	650,000	-	-	Direct
Dec 11, 2024	OLMA Olema Pharmaceuticals, Inc.	Sale(S)	55,907	$8.66	$484,155	Direct
Dec 11, 2024	OLMA Olema Pharmaceuticals, Inc.	Sale(S)	1,267	$9.39	$11,897	Direct
Dec 10, 2024	OLMA Olema Pharmaceuticals, Inc.	Sale(S)	52,328	$9.37	$490,313	Direct
Dec 9, 2024	OLMA Olema Pharmaceuticals, Inc.	Award(A)	204,750	-	$0	Direct

1-8 of 8 transactions

About Bohen Sean

Bohen Sean (SEC CIK 0001831218) files insider reports with the SEC as PRESIDENT AND CEO of Olema Pharmaceuticals, Inc. (OLMA).

Signal8 holds 4 ownership filings by Bohen Sean, all Form 4s, filed between Dec 11, 2024 and Feb 4, 2026. Those filings report 8 transactions, from Dec 9, 2024 to Feb 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Bohen Sean's filings is in SAN FRANCISCO, CA.

Recent filings by Bohen Sean

Feb 2, 2026: Grants or awards of OLMA derivative securities (2 lines, Form 4, code A).
Dec 26, 2025: Gift of OLMA shares (Form 4, code G).
Feb 28, 2025: Grant or award of OLMA derivative securities (Form 4, code A).
Dec 11, 2024: Open-market sales of OLMA shares (2 lines, Form 4, code S).
Dec 10, 2024: Open-market sale of OLMA shares (Form 4, code S).

Other insiders filing for Olema Pharmaceuticals, Inc. (OLMA)

O'Byrne Jason, CHIEF FINANCIAL OFFICER
Harmon Cyrus, Director
BVF PARTNERS L P/IL, Director
BUTITTA CYNTHIA M, Director
Garland J. Scott, Director
Hrustanovic Gorjan, Director

How to read Form 4 transaction codes